Pharmaceutical & Life Sciences News

Gene Therapy Companies Lead Biotech Higher During Merger Monday

Feb. 25, 2019, 2:13 PM

A string of deals, including a $4.8 billion bid by Roche for Spark Therapeutics, are driving shares of Nasdaq Biotech companies higher in pre-market trading, particularly those companies developing gene therapies.

Shares of uniQure are leading the charge, climbing 18 percent before the open after Cantor Fitzgerald analyst Elemer Piros wrote in a note to clients that uniQure “could be next.” Like Spark, uniQure develops gene therapies for hemophilia. Large caps like Novo Nordisk, Pfizer and Sanofi may seek to bolster their pipelines with uniQure’s technology, Piros said.

Peers like Crispr Therapeutics, Sangamo Therapeutics, Solid Biosciences and Editas Medicine are...

To read the full article log in. To learn more about a subscription click here.